Latest News in the pharma Industry
Research & Development
MAA submitted to EMA for patisiran for the treatment of hereditary ATTR amyloidosis
27 Dec 2017
Sanofi and Alnylam's patisiran MAA to be reviewed under accelerated assessment.
Read more
AMSBIO introduces highly efficient substrate for culturing ES/iPS cells
27 Dec 2017
iMatrix recombinant Laminin-511 E8 protein fragments permit ES/iPS cells to be maintained in xeno-free, feeder-free culture conditions enabling easy application in medical trials.
Read more.png)
FiH trial of new immunotherapy approach shows efficacy in antibiotic resistance
27 Dec 2017
Human polyclonal antibodies show promise as effective treatment.
Read more
Biogen and Ionis collaborate to identify novel therapies for the treatment of SMA
21 Dec 2017
New collaboration agreement to identify new antisense oligonucleotide drug candidates.
Read more
FDA clears myPKFiT for ADVATE to help personalize care for hemophilia A
19 Dec 2017
First and only FDA-cleared PK dosing software to support healthcare professionals in creating personalized dosing regimens for patients 16 and older with hemophilia A.
Read more
Collaboration to develop innovative technologies
20 Dec 2017
Project will innovate technologies in epigenetic characterisation for patient stratification in renowned precision medicine.
Read more
NIH study uncovers clues about why common cancer drug causes hearing loss
20 Dec 2017
Researchers find target to protect hearing during chemotherapy treatment.
Read more
Regeneron and ISA Pharma to advance immuno-oncology treatment
18 Dec 2017
Collaboration to conduct clinical trials of the combination treatment in both cervical and head-and-neck cancer.
Read more
Major breakthrough for new haemophilia A treatment
15 Dec 2017
Drug trials provide mind-blowing results.
Read more
New formulation of Oncaspar receives Marketing Authorization in Europe for patients with ALL
14 Dec 2017
Freeze-dried, or lyophilized, formulation aims to improve supply management by providing the same dosing regimen as liquid Oncaspar but with a three-times longer shelf life of up to 24 months.
Read more
CMC Biologics and Harpoon Therapeutics collaborate on exciting new TriTAC molecules
14 Dec 2017
First clinical candidate, HPN424, is in development for the treatment of metastatic prostate cancer and expected to enter Phase I clinical trials in 2018.
Read more
Sanofi ends development of Clostridium difficile vaccine
4 Dec 2017
IDMC concludes that the study is unlikely to meet its primary objective.
Read more